Related Experiment Video

Updated: Aug 16, 2026

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
06:18

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

Myocardial infarction risk and hormone replacement: differences between products

C S de Vries1, S E Bromley, R D T Farmer

  • 1Department of Pharmacoepidemiology, Postgraduate Medical School, University of Surrey, Daphne Jackson Road, Manor Farm Park, Guildford, Surrey, GU2 7WG, UK. c.de-vries@surrey.ac.uk

Maturitas
|July 26, 2005
PubMed

Insights

Hormone replacement therapy (HRT) use is linked to a lower risk of myocardial infarction (MI) and reduced fatality from MI. Different HRT regimens did not show varying risk levels for heart attack.

Area of Science:

  • Cardiovascular Health
  • Endocrinology
  • Pharmacology

Background:

  • Hormone replacement therapy (HRT) is widely used for menopausal symptoms.
  • The association between HRT and cardiovascular events, particularly myocardial infarction (MI), remains a significant area of research.
  • Understanding the comparative risks across different HRT regimens is crucial for clinical practice.

Purpose of the Study:

  • To determine the risk of myocardial infarction (MI) in hormone replacement therapy (HRT) users versus non-users.
  • To compare the risk of MI among various HRT regimens, modes of administration, and durations of use.

Main Methods:

  • A population-based cohort and case-control study design was employed.
  • Data were sourced from the UK General Practice Research Database.
  • Confounding factors were adjusted for, and analyses examined differences in HRT regimen, administration, and duration.

Main Results:

  • Both current and past HRT use were associated with a reduced risk of MI compared to no prior use.
  • Myocardial infarctions were less likely to be fatal in HRT users (OR(adj) 0.58; 95% CI 0.45-0.75).
  • No significant differences in MI risk were observed between current and past use, oral versus transdermal HRT, or different HRT regimens.

Conclusions:

  • Findings support the hypothesis that postmenopausal HRT use is associated with a decreased risk of acute myocardial infarction (AMI).
  • A protective effect of HRT is suggested by the difference in case fatality between users and non-users.
  • This study did not identify significant differences in MI risk among various HRT regimens.
Abstract

More Related Videos

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...